All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Francesc BoschScientific Advisory Board Member
Professor Francesc Bosch is the Head of the Department of Hematology at the University Hospital Vall d’Hebron, Barcelona, ES, and a Professor in the Department of Medicine at Universitat Autònoma de Barcelona, Barcelona, ES.
He completed his medical degree in 1988 at Universitat de Barcelona, Barcelona, ES, after which he underwent postgraduate training in hematology at the Hospital Clinic of Barcelona, finishing in 1992. In 1998, Prof. Bosch was awarded his PhD by the Universitat de Barcelona — his thesis was titled ‘Cyclin D1 gene in chronic lymphoproliferative disorders’. From 1998 until 2000, Prof. Bosch undertook a postdoctoral research position at the Institute for Cancer Genetics, Columbia University, NY, US, after which he returned to Barcelona to continue researching chronic lymphocytic leukemia (CLL).
Prof. Bosch was made Head of the Department of Hematology at the University Hospital Vall d’Hebron, Barcelona, ES, in 2009, where his research focuses on the molecular pathogenesis of CLL and the development of novel therapeutic approaches. He has been involved in the development of clinical trials, currently as Chair of the Spanish Group of CLL (GELLC), which is responsible for the development of Spanish CLL trials. Besides this, he has published more than 100 papers in peer-reviewed journals, including the New England Journal of Medicine (NEJM), Nature Medicine, Blood and the Journal of Clinical Oncology, among others. He has also authored or co-authored a number of reviews and book chapters on the subject of CLL and other lymphoproliferative disorders.
Positions of responsibility/awards:
- Chair of the Spanish Group of CLL (GELLC)
- Principal Investigator of Vall d’Hebron Institute of Oncology’s Experimental Hematology Group since 2016
- Main organizer of the Young Investigator’s Group on CLL, 2007
- Member of the European Project for Mantle Cell Lymphoma, 1996
- Founder Member of the Grup d’Estudi dels Linfomes a Catalunya i Balears (GELCAB), 1996
- Young Investigator Award, Paris, from the European Hematology Association, 1996
- Young Investigator Award from the Catalan Society of Hematology and Hemotherapy, 1994
- Extraordinary Doctorate Award, 1998, for his PhD studies